Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma

Pelland, Kevin; Mathews, Stephanie; Kamath, Anitha; Cohen, Paul; Hudnall, S. David; Cotta, Claudiu V.; Xu, Mina L.

doi:10.1097/pai.0000000000000615

Cited by 9 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD-L1 has been observed in a range of 15% and up to 50% of cases, whereas PD-L2 is frequently overexpressed in PM-LBCL ( > 60%). 27,65,66 Ki-67 is > 30%. PM-LBCL is negative for T-cell markers (Fig.…”

Section: Immunohistochemistrymentioning

confidence: 98%

See 1 more Smart Citation

Mediastinal Lymphoproliferative Disorders

Piña‐Oviedo

2021

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Lymphoproliferative disorders comprise 50% to 60% of all mediastinal malignancies in both children and adults. Primary mediastinal involvement is rare (∼5%), whereas secondary mediastinal involvement by systemic disease is more common (10% to 25%). Primary mediastinal disease is defined as involvement by a lymphoproliferative disorder of mediastinal lymph nodes, the thymus, and/or extranodal mediastinal organs without evidence of systemic disease at presentation. In this review, the clinical, radiologic, histopathologic, immunohistochemical, and genetic features of some of the most characteristic mediastinal lymphoproliferative disorders are presented. The entities discussed here include: classic Hodgkin lymphoma with emphasis on nodular sclerosis and mixed cellularity types, and non-Hodgkin lymphomas, including primary mediastinal (thymic) large B-cell lymphoma, mediastinal gray zone lymphoma, mediastinal diffuse large B-cell lymphoma, thymic marginal zone lymphoma, mediastinal plasmacytoma, T-lymphoblastic lymphoma, and anaplastic large cell lymphoma. Although not a malignant process, hyaline vascular Castleman disease is also discussed here as this disorder commonly involves the mediastinum. Despite multiple advances in hematopathology in recent decades, the day-to-day diagnosis of these lesions still requires a morphologic approach and a proper selection of immunohistochemical markers. For this reason, it is crucial for general pathologists to be familiar with these entities and their particular clinicoradiologic presentation.

show abstract

Section: Immunohistochemistrymentioning

confidence: 98%

“…The expression of the protein death ligands 1 and 2 (PD-L1/PD-L2) is variable. PD-L1 has been observed in a range of 15% and up to 50% of cases, whereas PD-L2 is frequently overexpressed in PM-LBCL (>60%) 27,65,66. Ki-67 is >30%.…”

Section: Non-hodgkin B-cell Lymphomasmentioning

confidence: 99%

Mediastinal Lymphoproliferative Disorders

Piña‐Oviedo

2021

Advances in Anatomic Pathology

View full text Add to dashboard Cite

show abstract

“…Higher frequencies and levels of CD123 expression are seen in malignant cells from patients with HCL than in from patients with the HCL variant phenotype [13,75,76], and CD123 is co-expressed with CD103 in most HCL cells [12,76]. CD123 expression has also been detected in malignant cells of patients with various non-Hodgkin lymphomas, with the highest frequency seen in patients with mediastinal gray zone lymphoma (MGZL; 71%) [77]. Its expression may aid in ruling out primary mediastinal large B-cell lymphoma in the differential diagnosis of MGZL.…”

Section: Cd123 Expression In Hematologic Malignanciesmentioning

confidence: 99%

Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy

Patnaik

Mughal

Brooks

et al. 2021

Leukemia & Lymphoma

View full text Add to dashboard Cite

Following the observation of interleukin 3 receptor a chain (IL-3Ra; CD123) upregulation on leukemia stem cells (LSCs) almost two decades ago, targeted treatment via CD123-diptheria toxin conjugates has now been tested in patients with diverse myeloid malignancies. Targeted eradication of LSCs could result in effective treatments for many challenging diseases initiated by these cells. Consequently, considerable effort has been directed toward targeting CD123 as a potential strategy for treating patients with hematologic malignancies in which CD123 is overexpressed. However, these therapies have had limited success so far, highlighting the need for suitable criteria to identify patients who could benefit from them. Given the diversity in CD123 expression across different hematologic malignancies, understanding CD123 expression patterns and the functional pathogenetic significance is crucial. Here, we review the methodologies available for CD123 assessment and discuss the biological and clinical characteristics of patients for whom CD123-targeting therapies may have a clinical impact.

show abstract

Malignant Hematopoietic Disorders of the Mediastinum

Piña‐Oviedo

2020

Diagnostic Thoracic Pathology

View full text Add to dashboard Cite

Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma

Cited by 9 publications

References 19 publications

Mediastinal Lymphoproliferative Disorders

Mediastinal Lymphoproliferative Disorders

Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy

Malignant Hematopoietic Disorders of the Mediastinum

Contact Info

Product

Resources

About